Abstract
HITHERTO no satisfactory method for the determination of the life of blood platelets has been described. Recently a method has been reported for determining the life of erythrocytes using diisopropylfluoro-phosphonate labelled with phosphorus-321. This method was based on the irreversible combination of this compound with esterases present on the red cell membrane. Since thrombocytes have also been shown to contain esterase, the same method suggested itself as a way of measuring the life of these cells. It seemed reasonable to assume that conditions similar to those described for red cells would be met. This implies that the decay of radioactivity associated with platelets would be entirely due to the destruction of these cells and therefore an index of their normal breakdown. This would only be true if no re-incorporation of labelled material in newly formed platelets were to take place. This assumption seems justified, since it has been shown that the only demonstrable metabolite of diisopropylfluorophosphonate in the human body is diisopropylphosphate. This compound is not further metabolized but quickly excreted in the urine. The labelled diiso-propylfluorophosphonate used was synthesized by Mr. Oosterbaan (M.B.L., Rijswijk) by a method to be reported in the near future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cohen, J. A., and Warringa, Mia G. P. J., J. Clin. Invest., 33, 459 (1954).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LEEKSMA, C., COHEN, J. Determination of the Life of Human Blood Platelets using Labelled Diisopropylfluorophosphonate. Nature 175, 552–553 (1955). https://doi.org/10.1038/175552b0
Issue Date:
DOI: https://doi.org/10.1038/175552b0
This article is cited by
-
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies
Drugs (2015)
-
Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice
Cell Death & Differentiation (2014)
-
Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
Annals of Hematology (2010)
-
Reserpine and human platelet 5-hydroxytryptamine
Experientia (1956)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.